Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Power List / 2021 / Small Molecules / Martin VanTrieste

Martin VanTrieste

President and Chief Executive Officer at Civica Rx

  • Profile

Meet Martin VanTrieste

Under VanTrieste’s leadership, Civica has expanded its membership to include more than 50 health systems across the US and has delivered more than 40 essential medications for hospitals, 11 of which are being used to treat COVID-19 patients. Most recently, Civica began providing its medicines to the US Department of Veterans Affairs and the US Department of Defense. During the peak of COVID-19 outbreaks in the US, VanTrieste led efforts to deliver 2.1 million containers of Civica medicines to the country’s Strategic National Stockpile.

“It was satisfying to see how the pharmaceutical industry responded quickly, collaboratively and effectively in response to COVID-19 – and improved our reputation, which has been damaged in recent years. We are in the biotechnology century. We will look back and say we learned more about human biology, how our DNA impacts the effectiveness of treatments, and how we can design drugs to target a specific disease. As a result, we will all benefit from cures and not just treatments for chronic conditions.”

False

Advertisement

Recommended

False

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.